Cannabidiol or CBD is a cannabis compound that does not produce psychoactive effects and has promising medicinal properties. Currently, CBD treatments are widely used in the United States, especially among young people suffering from epilepsy.

However, despite scientific evidence supporting its efficacy and safety, CBD is still considered illegal in many other places. This could soon change with the arrival of Epidiolex, the first CBD-based medication that is in the process of being approved by the FDA.

What is Epidiolex?

Epidiolex is a drug developed by GW Pharmaceuticals, in collaboration with Bayer, that contains 98% purified CBD extracted from the cannabis plant.

It is specifically designed to treat epilepsy that is resistant to other medications. The company has filed for approval with the FDA, the agency responsible for drug and food regulation in the United States. If approved, Epidiolex could become a milestone in the legalization of CBD as a medicine.

What is the potential of CBD as a medicine?

CBD has been the subject of numerous studies that have demonstrated its ability to treat a variety of diseases and ailments.

It has been found to have antipsychotic, anti-inflammatory, anxiolytic, anti-emetic and even anti-tumor properties. These properties make CBD a unique compound that could revolutionize medicine and pharmacology.

GW Pharmaceuticals’ role in CBD legalization.

GW Pharmaceuticals has an interesting history with the cannabis industry.

The company acquired Hortopharm, a pharmaceutical company that was involved in the genetic mapping of cannabis. It also has ties to the DEA (Drug Enforcement Administration) and High Times magazine.

These connections could be key to pushing for changes in federal legislation in the United States and making CBD legal.

What is the future of CBD legalization?

The legalization of CBD as a medicine is a complex and controversial issue. Although numerous scientific studies support its efficacy and safety, legal and political barriers make it difficult to access for those who could benefit from its use.

With the advent of Epidiolex, the doors could be opened to a significant change in the perception and regulation of CBD.

Conclusion

CBD has significant therapeutic potential and its legalization as a medicine is a desired goal for many. Epidiolex, the first CBD-based medicine could mark a milestone in the legalization of CBD in the United States.

Scientific evidence and success stories from those who have used CBD as a treatment support its efficacy and safety, which should be considered in regulatory decision-making.